Akouos Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 53

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $449M

Akouos General Information

Description

Developer of genetic therapies intended for auditory function restoration and preservation. The company focuses on precision medicine targeting sensorineural hearing loss, research into gene-based interventions for high-acuity hearing, and a focus on unmet clinical needs in auditory health, enabling healthcare providers and patients affected by disabling hearing conditions to access investigational treatments with potential for long-term improvement in sensory connectivity and physiological hearing outcomes.

Contact Information

Website
www.akouos.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 645 Summer Street
  • Suite 200
  • Boston, MA 02210
  • United States
Primary Industry
Drug Discovery
Parent Company
Vertical(s)
Corporate Office
  • 645 Summer Street
  • Suite 200
  • Boston, MA 02210
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Akouos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 01-Dec-2022 $449M Completed Generating Revenue
7. IPO 26-Jun-2020 Completed Generating Revenue
6. Early Stage VC (Series B) 03-Mar-2020 Completed Startup
5. Early Stage VC (Series A) 07-Aug-2018 Completed Startup
4. Seed Round 13-Nov-2017 Completed Startup
3. Accelerator/Incubator 05-Oct-2017 Completed Startup
2. Accelerator/Incubator 13-Oct-2016 Completed Startup
1. Accelerator/Incubator Completed Startup
To view Akouos’s complete valuation and funding history, request access »

Akouos Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed I 2,058,855 $0.000100 $0.02 $0.24 $0.24 1x $0.24 0.41%
Seed 25,622,520 $0.000100 $0.02 $0.28 $0.28 1x $0.28 5.06%
To view Akouos’s complete cap table history, request access »

Akouos Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of genetic therapies intended for auditory function restoration and preservation. The company focuses on preci
Drug Discovery
Boston, MA
53 As of 2026

Amsterdam, Netherlands
 

Tampa, FL
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Akouos Competitors (12)

One of Akouos’s 12 competitors is Audion Therapeutics, a Venture Capital-Backed company based in Amsterdam, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Audion Therapeutics Venture Capital-Backed Amsterdam, Netherlands
Pacira BioSciences Formerly VC-backed Tampa, FL
Spiral Therapeutics Venture Capital-Backed South San Francisco, CA
Acousia Therapeutics Venture Capital-Backed Tubingen, Germany
Sensorion Formerly VC-backed Montpellier, France
You’re viewing 5 of 12 competitors. Get the full list »

Akouos Patents

Akouos Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024397647-A1 Compositions and methods for treating hearing loss in a human subject having a defective otoferlin gene Pending 11-Dec-2023
EP-4823629-A1 Compositions and methods for treating hearing loss in a human subject having a defective otoferlin gene Pending 11-Dec-2023
WO-2025128559-A1 Compositions and methods for treating hearing loss in a human subject having a defective otoferlin gene Inactive 11-Dec-2023
AU-2023272166-A1 Compositions and methods for treating non-age-associated hearing impairment in a human subject Pending 19-May-2022
EP-4526452-A1 Compositions and methods for treating non-age-associated hearing impairment in a human subject Pending 19-May-2022 A61K48/005
To view Akouos’s complete patent history, request access »

Akouos Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Akouos Former Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
5AM Ventures Venture Capital Minority
Citadel Enterprise Americas Hedge Fund Minority
Cormorant Asset Management PE/Buyout Minority
Cowen Healthcare Investments Venture Capital Minority
EcoR1 Capital Venture Capital Minority
You’re viewing 5 of 21 investors. Get the full list »

Akouos ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Akouos’s complete esg history, request access »

Akouos FAQs

  • When was Akouos founded?

    Akouos was founded in 2016.

  • Where is Akouos headquartered?

    Akouos is headquartered in Boston, MA.

  • What is the size of Akouos?

    Akouos has 53 total employees.

  • What industry is Akouos in?

    Akouos’s primary industry is Drug Discovery.

  • Is Akouos a private or public company?

    Akouos is a Private company.

  • What is the current valuation of Akouos?

    The current valuation of Akouos is .

  • What is Akouos’s current revenue?

    The current revenue for Akouos is .

  • How much funding has Akouos raised over time?

    Akouos has raised $375M.

  • Who are Akouos’s investors?

    5AM Ventures, Citadel Enterprise Americas, Cormorant Asset Management, Cowen Healthcare Investments, and EcoR1 Capital are 5 of 21 investors who have invested in Akouos.

  • Who are Akouos’s competitors?

    Audion Therapeutics, Pacira BioSciences, Spiral Therapeutics, Acousia Therapeutics, and Sensorion are some of the 12 competitors of Akouos.

  • When was Akouos acquired?

    Akouos was acquired on 01-Dec-2022.

  • Who acquired Akouos?

    Akouos was acquired by Lilly USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process